NASDAQ
SCLX

Scilex Holding Company

Drug Manufacturers-General
Healthcare

Prices are adjusted according to historical splits.

Scilex Holding Company Stock Price

Vitals

Today's Low:
$2.37
Today's High:
$2.54
Open Price:
$2.47
52W Low:
$2.37
52W High:
$16.9
Prev. Close:
$2.41
Volume:
707262

Company Statistics

Market Cap.:
$462.07 million
Book Value:
0.07
Revenue TTM:
$46.46 million
Operating Margin TTM:
-169.27%
Gross Profit TTM:
$27.24 million
Profit Margin:
-115.77%
Return on Assets TTM:
-45.42%
Return on Equity TTM:
0%

Company Profile

Scilex Holding Company had its IPO on 2021-03-05 under the ticker symbol SCLX.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. Scilex Holding Company has a staff strength of 100 employees.

Stock update

Shares of Scilex Holding Company opened at $2.47 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.37 - $2.54, and closed at $2.44.

This is a +1.24% increase from the previous day's closing price.

A total volume of 707,262 shares were traded at the close of the day’s session.

In the last one week, shares of Scilex Holding Company have slipped by -21.29%.

Scilex Holding Company's Key Ratios

Scilex Holding Company has a market cap of $462.07 million, indicating a price to book ratio of 0 and a price to sales ratio of 14.1851.

In the last 12-months Scilex Holding Company’s revenue was $46.46 million with a gross profit of $27.24 million and an EBITDA of $-74500000. The EBITDA ratio measures Scilex Holding Company's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Scilex Holding Company’s operating margin was -169.27% while its return on assets stood at -45.42% with a return of equity of 0%.

In Q2, Scilex Holding Company’s quarterly earnings growth was a positive 0% while revenue growth was a positive 58.7%.

Scilex Holding Company’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.34 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Scilex Holding Company’s profitability.

Scilex Holding Company stock is trading at a EV to sales ratio of 21.1847 and a EV to EBITDA ratio of -14.7839. Its price to sales ratio in the trailing 12-months stood at 14.1851.

Scilex Holding Company stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$126.46 million
Total Liabilities
$103.58 million
Operating Cash Flow
$0
Capital Expenditure
$146000
Dividend Payout Ratio
0%

Scilex Holding Company ended 2024 with $126.46 million in total assets and $0 in total liabilities. Its intangible assets were valued at $126.46 million while shareholder equity stood at $10.42 million.

Scilex Holding Company ended 2024 with $0 in deferred long-term liabilities, $103.58 million in other current liabilities, 15000.00 in common stock, $-433316000.00 in retained earnings and $13.48 million in goodwill. Its cash balance stood at $34.12 million and cash and short-term investments were $34.12 million. The company’s total short-term debt was $35,132,000 while long-term debt stood at $0.

Scilex Holding Company’s total current assets stands at $69.25 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $27.57 million compared to accounts payable of $11.41 million and inventory worth $3.11 million.

In 2024, Scilex Holding Company's operating cash flow was $0 while its capital expenditure stood at $146000.

Comparatively, Scilex Holding Company paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$2.44
52-Week High
$16.9
52-Week Low
$2.37
Analyst Target Price
$

Scilex Holding Company stock is currently trading at $2.44 per share. It touched a 52-week high of $16.9 and a 52-week low of $16.9. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $4.47 and 200-day moving average was $6.51 The short ratio stood at 5.18 indicating a short percent outstanding of 0%.

Around 4280.4% of the company’s stock are held by insiders while 1056.5% are held by institutions.

Frequently Asked Questions About Scilex Holding Company

The stock symbol (also called stock or share ticker) of Scilex Holding Company is SCLX

The IPO of Scilex Holding Company took place on 2021-03-05

Similar Industry Stocks (Drug Manufacturers-General)

Last Price
Chg
Chg%
$121.85
-8.3
-6.38%
$1838.6
-45.35
-2.41%
ICICI BANK LTD. (ICICIBANK)
$990.9
12.55
+1.28%
$23.92
0
0%
$119.05
-4.9
-3.95%
$16.08
0.7
+4.55%
$21.27
-0.02
-0.09%
$2893
-150.25
-4.94%
$26.24
-1.38
-5%
$76.73
-0.25
-0.32%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Scilex Holding Company, a biopharmaceutical company, focuses on acquiring, developing, and commercializing non-opioid management products for the treatment of acute and chronic pain. It offers ZTlido, a prescription lidocaine topical product for the relief of neuropathic pain related with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also develops SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trial for the treatment of low back pain; and SP-104 (4.5 mg), a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Address

960 San Antonio Road, Palo Alto, CA, United States, 94303